The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT-EHA CAR-T 2019 | Anti-BCMA CAR T-cell therapy for multiple myeloma: latest studies
Alfred Garfall
• 15 Mar 2019
Alfred Garfall, MD, MS University of Pennsylvania, Pennsylvania, PA, discusses the latest results looking at anti-BCMA CAR T-cell therapy for multiple myeloma. Dr Garfall was speaking at at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
